GlobeImmune Presents Updated GI-6301 P1 Results On CTOS, Berlin

(RTTNews) - Cancer drugs developer GlobeImmune, Inc. (GBIM) Friday said updated results of its GI-6301 Phase 1 trial in eleven chordoma patients were presented in 2014 Connective Tissue Oncology Site, CTOS annual meeting in Berlin.

Out of the 11 Chordoma patients studied, 7 patients left the study due to disease progression. Out of the four continuing patients, three had progressive disease at study entry, the company said.

Of all the patients studied, 62 percent had post-administration brachyury-specific T cell immune responses, GlobeImmune said.

There was one partial response by RECIST that has continued beyond twelve months.

GlobeImmune said common adversities seen in the study were moderate injection site reactions.

"We believe these initial results with GI-6301 as a single agent provide a rationale for evaluating this product in a randomized Phase 2 study in chordoma," said Timothy Rodell, CEO of GlobeImmune.